Bionano Genomics, Inc. (BNGO) News
Filter BNGO News Items
BNGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNGO News Highlights
- BNGO's 30 day story count now stands at 11.
- Over the past 28 days, the trend for BNGO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about BNGO are CELL, DNA and STEM.
Latest BNGO News From Around the Web
Below are the latest news stories about BIONANO GENOMICS INC that investors may wish to consider to help them evaluate BNGO as an investment opportunity.
Bionano Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that on September 18, 2023, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted an inducement award consisting of a non-qualified stock option to purchase 106,000 shares of common stock to Gülsen Kama, the Company’s new Chief Financial Officer, under the Company’s 2020 Inducement Plan, as amended. The Compensation Committee approved the award as an |
Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should KnowBionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGMBionano original equipment manufacturing (OEM) partner Ecobono obtained reagent Class I registration and approval for Bionano’s DNA isolation kits for optical genome mapping (OGM) from China's National Medical Products Administration (NMPA)Reagents can be utilized for in vitro diagnostics (IVD) use in ChinaWith this NMPA registration, Ecobono can sell OGM reagents to independent clinical laboratories and Chinese hospitals SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasd |
Largest Study of Mendelian Disease Highlights how OGM, alongside other Techniques, May Enhance Success Rates in Identifying Molecular Causes of Genetic DiseaseSAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families. The study authors conducted a comprehensive analysis of samples from the cohort in which non-sequencing-based challenges were encountered, and then reanalyzed samples using exome sequencing (ES), whole-genome sequencing (WG |
The 3 Best High-Risk, High-Reward Stocks to Buy Now: September 2023The stock market's multiple challenges should dissipate soon, making now a good time to buy high-risk, high-reward stocks. |
Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and WES for Evaluation of Pediatric LeukemiaSAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from researchers at the German Cancer Consortium (DKTK) showing the utility of optical genome mapping (OGM) and whole-exome sequencing (WES) in better understanding the mutational landscape of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Researchers compared the analysis of 60 pediatric BCP-ALL samples using traditional cytogenetic methods against |
7 F-Rated Meme Stocks to Avoid Like the PlagueThese popular meme stocks should be avoided at all costs – no matter what you may see on social media. |
Bionano Announces Publication Demonstrating Utility of OGM as an Alternative to KT and CMA for Evaluating CRISPR-Edited Cells as Part of Stem Cell Therapy DevelopmentSAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic structural alterations that may limit their usefulness for stem cell therapy. The study authors found t |
These Are the ONLY 3 Meme Stocks to Consider in August 2023While all meme stocks have been crushed, there are still a few meme stocks that look poised to eventually succeed. |
15 Most Shorted Stocks That Are Loved By AnalystsIn this piece, we will take a look at the 15 most shorted stocks that are loved by analysts. If you want to skip our introduction to short selling, then jump ahead to 5 Most Shorted Stocks That Are Loved By Analysts. Short selling is a tricky game. Rapid share price appreciations can stretch a […] |